(Total Views: 552)
Posted On: 05/18/2021 12:23:10 PM
Post# of 154120
Figgs wrote:
"The FDA will go back to the CD-10 and CD-12 trials and say the same thing. That we did not pass our primary end point. They will be right and we have no way of changing that."
my response:
Dear Nader: we CYDY investors ask you to contact Janet Woodcock to "tell her" to please apologize for their "mistaken" comments, and publish a widely distributed correction to all false or mistaken comments.
The FDA letter did not merely say leronlimab missed endpoints.
The letter said in CD10, leronlimab had "no effect" on the covid19 virus.
No effect yet known accepted "Clinical Significance" on Primary Endpoint.
No effect yet known accepted "Statistical Significance" on Secondary Endpoint of vital NEWS2
Wow. Blatant lies. Motive? Who pushed this letter thru?
"The FDA will go back to the CD-10 and CD-12 trials and say the same thing. That we did not pass our primary end point. They will be right and we have no way of changing that."
my response:
Dear Nader: we CYDY investors ask you to contact Janet Woodcock to "tell her" to please apologize for their "mistaken" comments, and publish a widely distributed correction to all false or mistaken comments.
The FDA letter did not merely say leronlimab missed endpoints.
The letter said in CD10, leronlimab had "no effect" on the covid19 virus.
No effect yet known accepted "Clinical Significance" on Primary Endpoint.
No effect yet known accepted "Statistical Significance" on Secondary Endpoint of vital NEWS2
Wow. Blatant lies. Motive? Who pushed this letter thru?
(16)
(0)
